HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prospect Of L’Oreal Share Buyback Excites Investors

This article was originally published in The Rose Sheet

Executive Summary

Sanofi SA has the cash to buy back about $12 billion worth of shares in its company that are currently owned by French beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says during Sept. 13 conference. L’Oreal CEO Agon suggested in recent earnings call that his firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

You may also be interested in...



Nestle Increases Health Care Investment With Galderma Control

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.

Nestle Increases Health Care Investment With Galderma Control

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.

L’Oreal Buys Back Shares From Nestle, Sells Galderma Stake

To finance a deal to purchase more than €6 billion of its own shares back from Nestle SA, L’Oreal SA has given up its half of skin-care company Galderma.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel